- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
VistaGen Therapeutics Inc (VTGN)
"VistaGen Therapeutics Inc stock price live, this page displays NASDAQ VTGN stock exchange data. View the VTGN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the VistaGen Therapeutics Inc real time stock price chart below.
What Is the VistaGen Therapeutics Inc Stock Price Today?
The VistaGen Therapeutics Inc stock price today is 2.815.
What Is the Stock Symbol for VistaGen Therapeutics Inc?
The stock symbol for VistaGen Therapeutics Inc is ""VTGN.""
What Stock Exchange Does VistaGen Therapeutics Inc Trade On?
VistaGen Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is VistaGen Therapeutics Inc a Good Stock to Buy?
Determining whether VistaGen Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VTGN quote. (ISIN: US92840H4002)"
What Is the VistaGen Therapeutics Inc Stock Price Today?
The VistaGen Therapeutics Inc stock price today is 2.815.
What Is the Stock Symbol for VistaGen Therapeutics Inc?
The stock symbol for VistaGen Therapeutics Inc is ""VTGN.""
What Stock Exchange Does VistaGen Therapeutics Inc Trade On?
VistaGen Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is VistaGen Therapeutics Inc a Good Stock to Buy?
Determining whether VistaGen Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VTGN quote. (ISIN: US92840H4002)"
NASDAQ
Currency in USD
2.815
+0.115(+4.26%)
Closed
Pre Market
2.850+0.035(+1.24%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.670
2.860
52 wk Range
2.220
5.740
VTGN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.6702.860
52 wk Range
2.2205.740
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VTGN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
13.000
Upside
+361.81%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
VistaGen Therapeutics Inc Company Profile
Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company’s product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women’s health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders. In addition, the company’s clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
VistaGen Therapeutics Inc Earnings Call Summary for Q3/2025
- VistaGen reports Q3 FY2025 net loss of $14.1M, up from $6.4M YoY, with R&D expenses rising to $11.3M
- Company focuses on intranasal treatments for neurocircuitry, advancing five clinical-stage product candidates
- Stock rose 4.01% in regular trading and 3.56% after hours, closing at $2.951
- Cash and securities stand at $88.6M; top-line results for Fasadienol in social anxiety disorder expected in 2025
- CEO expresses optimism about pipeline, highlighting unique mechanism of action as key differentiator
Last Updated: 2025/02/14, 00:56
Read Full TranscriptCompare VTGN to Peers and Sector
Metrics to compare | VTGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVTGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.7x | −0.8x | −0.6x | |
PEG Ratio | −0.05 | 0.00 | 0.00 | |
Price/Book | 1.0x | 0.6x | 2.6x | |
Price / LTM Sales | 116.4x | 6.3x | 3.0x | |
Upside (Analyst Target) | 326.3% | 547.1% | 51.6% | |
Fair Value Upside | Unlock | 36.2% | 9.3% | Unlock |
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 13.000
(+361.81% Upside)
Earnings
Latest Release
Aug 10, 2023
EPS / Forecast
-0.94 / -2.25
Revenue / Forecast
170.00K / 340.00K
FAQ
What Is the VistaGen Therapeutics (VTGN) Stock Price Today?
The VistaGen Therapeutics stock price today is 2.815
What Stock Exchange Does VistaGen Therapeutics Trade On?
VistaGen Therapeutics is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for VistaGen Therapeutics?
The stock symbol for VistaGen Therapeutics is "VTGN."
What Is the VistaGen Therapeutics Market Cap?
As of today, VistaGen Therapeutics market cap is 81.25M.
What is VistaGen Therapeutics Earnings Per Share?
The VistaGen Therapeutics EPS is -1.55.
From a Technical Analysis Perspective, Is VTGN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.